Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Instituto do Cancer do Estado de São Paulo
KaliVir Immunotherapeutics
Sotio Biotech Inc.
Endeavor Biomedicines, Inc.
Takeda
Perspective Therapeutics
Novartis
VM Oncology, LLC
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Incyte Corporation
Incyte Corporation
Incyte Corporation
Turnstone Biologics, Corp.
SOLTI Breast Cancer Research Group
Symphogen A/S
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
Xencor, Inc.
Ascentage Pharma Group Inc.
Incyte Corporation
AbbVie
MacroGenics
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Incyte Corporation
Mayo Clinic
Centre Hospitalier Universitaire de Nice
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
Mannkind Corporation